Axel Grothey

7.8k total citations · 1 hit paper
93 papers, 3.8k citations indexed

About

Axel Grothey is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Axel Grothey has authored 93 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Axel Grothey's work include Colorectal Cancer Treatments and Studies (71 papers), Cancer Treatment and Pharmacology (43 papers) and Gastric Cancer Management and Outcomes (17 papers). Axel Grothey is often cited by papers focused on Colorectal Cancer Treatments and Studies (71 papers), Cancer Treatment and Pharmacology (43 papers) and Gastric Cancer Management and Outcomes (17 papers). Axel Grothey collaborates with scholars based in United States, Germany and Italy. Axel Grothey's co-authors include Dorothea Wagner, Johannes Haerting, G. Kleber, Wolfgang E. Fleig, Wilfried Grothe, Richard M. Goldberg, Hans‐Joachim Schmoll, Daniel J. Sargent, Wieland Voigt and Eric Van Cutsem and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Axel Grothey

91 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data

2006 919 citations Dorothea Wagner, Wilfried Grothe et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Axel Grothey United States	29	2.6k	1.4k	896	685	607	93	3.8k
Axel Grothey United States	23	2.0k 0.8×	1.0k 0.7×	654 0.7×	515 0.8×	360 0.6×	82	3.3k
Vincenzo Catalano Italy	40	3.1k 1.2×	1.6k 1.1×	1.4k 1.6×	1.2k 1.7×	900 1.5×	124	5.1k
Tomohiro Nishina Japan	35	2.7k 1.0×	2.2k 1.6×	665 0.7×	1.1k 1.6×	645 1.1×	231	4.3k
Markus Borner Switzerland	43	3.0k 1.2×	1.8k 1.3×	1.8k 2.0×	1.1k 1.7×	541 0.9×	126	5.6k
Jan Stoehlmacher Germany	26	3.4k 1.3×	1.8k 1.3×	1.7k 1.9×	1.1k 1.7×	980 1.6×	57	5.3k
Smitha Krishnamurthi United States	25	2.2k 0.8×	939 0.7×	834 0.9×	487 0.7×	493 0.8×	126	3.3k
Bruce J. Giantonio United States	31	3.4k 1.3×	1.6k 1.1×	1.3k 1.4×	729 1.1×	559 0.9×	124	5.0k
Michelle R. Mahoney United States	32	3.4k 1.3×	1.7k 1.2×	757 0.8×	1.2k 1.7×	1.3k 2.2×	71	4.8k
Yasutsuna Sasaki Japan	35	2.6k 1.0×	1.2k 0.9×	1.2k 1.4×	435 0.6×	455 0.7×	193	4.0k
J. Załuski Poland	13	3.7k 1.4×	1.7k 1.2×	574 0.6×	816 1.2×	929 1.5×	23	4.5k

Countries citing papers authored by Axel Grothey

Since Specialization

Citations

This map shows the geographic impact of Axel Grothey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Grothey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Grothey more than expected).

Fields of papers citing papers by Axel Grothey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Grothey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Grothey. The network helps show where Axel Grothey may publish in the future.

Co-authorship network of co-authors of Axel Grothey

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Grothey. A scholar is included among the top collaborators of Axel Grothey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Grothey. Axel Grothey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). 3529–3529. 12 indexed citations

Shi, Qian, Alberto Sobrero, Anthony F. Shields, et al.. (2017). Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.. Journal of Clinical Oncology. 35(15_suppl). LBA1–LBA1. 10 indexed citations

Bendell, Johanna C., Bert H. O’Neil, Alexander Starodub, et al.. (2017). Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. Journal of Clinical Oncology. 35(4_suppl). 593–593. 11 indexed citations

Ciardiello, Fortunato, Lisa Salvatore, Stefano Cascinu, et al.. (2016). Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. Annals of Oncology. 27. iv44–iv44.

Salvatore, Lisa, Fortunato Ciardiello, Stefano Cascinu, et al.. (2016). Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Annals of Oncology. 27. iv47–iv47. 1 indexed citations

Grothey, Axel, Eric Van Cutsem, J. Kalmus, et al.. (2015). O-011 Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC). Annals of Oncology. 26. iv111–iv111. 2 indexed citations

Singh, Preet Paul, Qian Shi, Nathan R. Foster, et al.. (2015). Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).. Journal of Clinical Oncology. 33(15_suppl). 3531–3531. 4 indexed citations

Hurwitz, Herbert I., Tanios Bekaii‐Saab, Johanna C. Bendell, et al.. (2014). Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin® Registry – Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study. Clinical Oncology. 26(6). 323–332. 24 indexed citations

Goetz, Matthew P., Joel M. Reid, Sumithra J. Mandrekar, et al.. (2013). UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Investigational New Drugs. 31(6). 1559–1567. 16 indexed citations

10.

Yoon, Harry H., Qian Shi, William R. Sukov, et al.. (2012). Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas. Clinical Cancer Research. 18(2). 546–554. 116 indexed citations

11.

Bendell, Johanna C., Tanios Bekaii‐Saab, Allen Lee Cohn, et al.. (2012). Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. The Oncologist. 17(12). 1486–1495. 79 indexed citations

12.

Wagner, Dorothea, et al.. (2010). Novel Chemotherapy Combinations in Advanced Gastric Cancer: an Updated Meta-Analysis. IRIS. 2 indexed citations

13.

Costello, Brian A., J. Randolph Hecht, & Axel Grothey. (2009). Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review. Journal of Clinical Oncology. 27(15_suppl). 4054–4054. 4 indexed citations

14.

Love, Neil, Carma L. Bylund, L. M. Ellis, et al.. (2009). Adjuvant therapy report card: Patients with stage II/III colon cancer grade their oncologists. Journal of Clinical Oncology. 27(15_suppl). 4045–4045. 1 indexed citations

15.

Goldberg, Richard M., C.-H. Köhne, Michel Seymour, et al.. (2007). A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 25(18_suppl). 4011–4011. 7 indexed citations

16.

Bylund, Carma L., Neal J. Meropol, John L. Marshall, et al.. (2007). How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. Journal of Clinical Oncology. 25(18_suppl). 4020–4020. 10 indexed citations

17.

Wagner, Dorothea, et al.. (2005). Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. CD004064–CD004064. 51 indexed citations

18.

Grothey, Axel & Matthew P. Goetz. (2004). Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer. Clinical Colorectal Cancer. 4. S37–S42. 12 indexed citations

19.

Dempke, Wolfram C. M., et al.. (2001). Human hematopoietic growth factors: old lessons and new perspectives.. PubMed. 20(6D). 5155–64. 28 indexed citations

20.

Dempke, Wolfram C. M., Wieland Voigt, Axel Grothey, Bridget T. Hill, & Hans‐Joachim Schmoll. (2000). Cisplatin resistance and oncogenes - a review. Anti-Cancer Drugs. 11(4). 225–236. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact